Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development

In order to identify cellular pathways associated with therapy-resistant aggressive lymphoma, we generated rituximab-resistant cell lines (RRCL) and found that the acquirement of rituximab resistance was associated with a deregulation in glucose metabolism and an increase in the apoptotic threshold...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Juan J., Singh, Anil, Xue, Kai, Mavis, Cory, Barth, Matthew, Yanamadala, Vivek, Lenz, Peter, Grau, Michael, Lenz, Georg, Czuczman, Myron S., Hernandez-Ilizaliturri, Francisco J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790518/
https://www.ncbi.nlm.nih.gov/pubmed/29423101
http://dx.doi.org/10.18632/oncotarget.23425

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790518/
https://www.ncbi.nlm.nih.gov/pubmed/29423101
http://dx.doi.org/10.18632/oncotarget.23425

Ejemplares similares